Results 131 to 140 of about 740 (167)

Anti-CD123 CAR-T therapy combined with autologous SCT and venetoclax maintenance in refractory BPDCN ineligible for allogeneic transplantation: a case report and review of the literature. [PDF]

Front Immunol
Yang F, Li D, Lei Y, Liu R, Fu Z, Ma L, Deng B, Ke X, Hu K.   +8 more
europepmc   +1 more source

Tagraxofusp after Transplant: A Phase I Safety Study of Post-HCT Maintenance in CD123+ Myeloid Malignancies

Kasner, M
core   +1 more source

Real-world study of tagraxofusp monotherapy in relapsed or refractory blastic plasmacytoid dendritic cell neoplasm

Leukemia and Lymphoma
Patients with relapsed/refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) have limited treatment options. Tagraxofusp is the only drug approved for BPDCN.
Marco Herling, Cristina Papayannidis, Ann-Kristin Schmaelter   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm

Hematology/Oncology Clinics of North America, 2020
Tagraxofusp, a CD123-targeted immunotoxin, is the first FDA-approved treatment for patients 2 years and older with blastic plasmacytoid dendritic cell neoplasm (BPDCN). It has been shown to be safe and effective in treatment-naïve and previously treated adult patients, with high rates of successful bridging to hematopoietic stem cell transplantation ...
Naveen Pemmaraju
exaly   +3 more sources

Reversible Myocardial Edema Secondary to Tagraxofusp-Induced Capillary Leak Syndrome

JACC: CardioOncology, 2021
[Figure: see text]
Juan Lopez-Mattei, Naveen Pemmaraju, Danielle Hammond   +2 more
exaly   +3 more sources

Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm

Expert Review of Anticancer Therapy, 2020
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy that previously lacked standardized therapeutic approaches. CD123 (interleukin-3 receptor alpha unit) is highly expressed in many hematologic malignancies, including BPDCN. Tagraxofusp-ezrs (tagraxofusp from herein) is an agent that consists of interleukin-
Naveen Pemmaraju, Deborah McCue
exaly   +3 more sources

Relapse of tagraxofusp treated blastic plasmacytoid dendritic cell neoplasm with loss of CD123 expression [PDF]

Journal of Hematopathology, 2021
AbstractTagraxofusp, a CD123-based-targeted immunotherapy, was recently approved to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) with excellent response. Also, a subset of BPDCN shows resistance to tagraxofusp. These resistant cases continue to express CD123, which forms the basis of the continued utility of tagraxofusp in newer ...
Mehdi Nassiri, Rohit Gulati, Tareq Salous   +2 more
exaly   +3 more sources

Evaluating tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Expert Opinion on Pharmacotherapy, 2022
Unique among hematologic malignancies, blastic plasmacytoid dendritic cell neoplasm (BPDCN) affects multiple compartments including bone marrow, hematologic, lymphatic, dermatologic, and central nervous systems (CNS). Treating BPDCN is challenging, historically, as patients display refractoriness to chemotherapy and absence of long-term remissions in ...
Naveen Pemmaraju, Nathaniel Wilson
exaly   +3 more sources